Bio-Rad Laboratories, Inc. Class A Common Stock vs Alphabet Inc Class A — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.04 (market cap $9.43B), while Alphabet Inc Class A trades at $342.47 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 445.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GOOGL | |
|---|---|---|
Market Cap | $9.43B | $4.20T |
Sector | Health | Media |
52-Week High | $356.25 | $402.62 |
52-Week Low | $241.71 | $199.32 |
Enterprise Value | $9.18B | $4.09T |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Alphabet (GOOGL) is trading at $341.48, down 4.49% over the past 24 hours, with a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 85% analyst buy rating support the positive outlook, though technical indicators show near-term pressure with support at $341 and resistance at $350.
GOOGL presents a compelling long-term investment opportunity with robust profitability (54.77% net margin) and AI-driven growth potential, though investors face near-term technical weakness and regulatory risks. The consensus price target of $426.28 implies significant upside from current levels, supported by strong cash flow generation and strategic AI investments.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →